Rare Cancer Series | Cutaneous T-cell Lymphoma

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.

Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.

Pei-Ling Chen, MD, PhD, says management of cutaneous T-cell lymphoma requires a multidisciplinary team of specialists including dermatologists and radiation oncologists.

Pei-Ling Chen, MD, PhD, discusses the incidence of CTCL.

Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.

Although cutaneous T-cell lymphoma, a group of non-Hodgkin T-cell lymphomas, remains a rare disease, incidence has increased steadily since the 1970s.